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1LETTER TO THE EDITOR
egylated TNF- Receptor Does Not Prevent Acute
raft-versus-Host Disease in the Dog Leukocyte
ntigen-Nonidentical Unrelated Canine Model
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dIt has been suggested that cytokines in general and
umor necrosis factor  (TNF-) in particular have
mportant roles in the initiation of graft-versus-host
isease (GVHD) [1,2]. Several recent publications
ave indicated that neutralization of TNF- may be
n effective treatment for acute or chronic GVHD
3-5]. Neutralization may be accomplished with a
onoclonal anti-TNF- (inﬂiximab) or by the use of
soluble TNF receptor/immunoglobulin fusion pro-
ein (etanercept). An experimental polyethylene glycol
PEG)-treated form of the soluble TNF receptor/
mmunoglobulin (PEG sTNF-RI) has been recently
onstructed with the potential of decreasing immuno-
enicity and extending circulating half-life [6]. PEG
TNF-RI has been tested preclinically in the rat,
ynomolgus monkey, chimpanzee, and baboon as a
otential inhibitor against manifestations of rheuma-
oid arthritis in patients [7]. This new TNF- inhib-
tor appeared to be an ideal candidate for evaluating
he role of TNF- in GVHD in the preclinical canine
odel.
We previously observed uniformly fatal acute
VHD in dogs when a dog leukocyte antigen (DLA)
onidentical recipient received 920-cGy total body
rradiation (TBI) immediately before hematopoi-
tic cell transplantation (HCT). On average, severe
VHD was observed within 14 days without treat-
ent and delayed to day 20 when dogs were treated
ith the antimetabolite methotrexate (MTX) [8,9]. In
his study, we investigated whether PEG sTNF-RI,
dministered in combination with MTX, could pre-
ent or delay the initiation of GVHD in the DLA-
onidentical HCT model.
In preliminary in vitro studies, we ﬁrst tested the
ytotoxic effects of recombinant human TNF-
rhTNF-) or canine TNF-, derived from lipopo-
ysaccharide-treated canine peripheral blood mono-
ytes, against the cell line WEHI using a standard
etrazolium dye (3-(4,5-dimethylthiazil-2-yl)-2,5-di-
henyl tetrazolium bromide) reduction assay. Canine
NF- and rhTNF- were essentially equivalent in
nducing cytotoxicity in a dose-dependent manner in
he range of 1-8 ng/mL of rhTNF- (Figure 1). Next, d
198e assessed the inhibitory capacity of PEG sTNF-RI
n cytotoxicity of recombinant canine TNF- and
hTNF- against WEHI cells. A concentration of 2.0
g/mL of PEG sTNF-RI inhibited by 50% the cyto-
oxicity mediated by 2 ng/mL of canine or human
NF- (Figure 1). Similar concentration ratios of
nﬂiximab or etanercept to TNF- have been shown
o inhibit TNF-mediated cytotoxicity against WEHI
ells [10].
We then evaluated the effect of PEG sTNF-RI on
dogs given 920-cGy TBI followed by HCT from
LA-nonidentical donors. In the ﬁrst group of 2
ecipients, PEG sTNF-RI was administered twice
eekly starting on the day after TBI. In the second
roup of 3 dogs, PEG sTNF-RI was administered
very other day, starting the day before TBI. The dose
f PEG sTNF-RI was 0.5 mg/kg, equivalent to
he dose of etanercept recommended for children for
he treatment of rheumatoid arthritis and within the
ange of doses of PEG sTNF-RI found to be effective in
ecreasing induced arthritis in Lewis rats [11]. MTX
as administered at 0.4 mg/kg intravenously on days
, 3, 6, and 11 and once weekly thereafter, as previ-
usly described [8,9]. HCT consisted of a mean of
.6  108 marrow cells/kg (range, 1.8-7.8  108 mar-
ow cells/kg) infused intravenously immediately after
BI (day 0) and a mean of 2  108 peripheral blood
uffy coat cells/kg (range, 1.25-2.7  108 peripheral
lood buffy coat cells/kg) infused on day 1. Toxicities
ere mainly gastrointestinal and hematologic owing
o the effects of the 920-cGy TBI and MTX and
omparable to those observed in historical controls.
The results are presented in Table 1. All dogs
ngrafted with complete donor chimerism. Four of 5
ogs developed acute GVHD and 30% weight loss,
esulting in the need to euthanize between 13 and 18
ays, independent of the PEG sTNF-RI treatment
egimen. GVHD was conﬁrmed by histopathology on
ecropsied tissue biopsies. The median number of
ays to survival was 17.5 compared with 20 days for 35
istorical treated dogs in 1 study [8] and 19 days for 29
ogs in another study [9]. Statistical analysis of the
ata using a 2-sided Mann-Whitney U test compari-
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Letter to the Editor 1199on of nonparametric samples failed to note a signif-
cant improvement in survival in the dogs treated with
EG sTNF-RI plus MTX over dogs treated with
TX alone (P  .05). The ﬁfth dog was euthanized
n day 13, with histopathology conﬁrming herpes
irus infection.
Serum levels of PEG sTNF-RI were determined
y enzyme-linked immunosorbent assay on blood
amples 24 hours after treatment and daily thereafter
Figure 2). The results indicated that mean serum
evels of PEG sTNF-RI, although variable for the
ogs treated twice weekly and moderately less so for
he dogs treated every other day, were comparable
etween the 2 groups. These levels of PEG sTNF-RI
ere similar to those reported for the same dose (0.5
g/kg) of PEG sTNF-RI administered on a weekly
asis in chimpanzees [7].
Our results indicate that PEG sTNF-RI in com-
ination with MTX failed to induce graft-versus-host
olerance, and long-term survival was not observed in
igure 1. Cytotoxicity of rhTNF- and canine monocyte-derived
anine TNF- against WEHI cells. Canine peripheral blood-de-
ived monocytes were incubated for 18 hours in Iscove Modiﬁed
ulbecco Medium with 10% dog serum and 25 ng/mL lipopoly-
accharide. Cytotoxicity was determined after adding monocyte-
erived supernatant in 5-fold dilutions to WEHI cells (top; abscissa
units listed as reciprocal of dilution) or with 5-fold dilutions of
hTNF- starting with 8 ng/mL (top; abscissa B units listed as
anograms per milliliter). Bottom, Titrations of PEG sTNF-RI
ere added to WEHI cells in the presence or absence of 2 ng/mL
hTNF- or recombinant canine (rc) TNF-. Toxicity for both
xperiments was determined by a 3-(4,5-dimethylthiazil-2-yl)-2,5-
iphenyl tetrazolium bromide assay after an 18-hour incubation
eriod.hese DLA-nonidentical HCT recipients. We believe Ta
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Letter to the Editor1200he model is valid for evaluating GVHD, because it
as been used previously to identify clinically relevant
rug combinations, such as MTX/cyclosporine [9],
TX/tacrolimus [12], and mycophenolate mofetil/
yclosporine [13]. A possible explanation for lack of
fﬁcacy is that the role played by TNF- in this model
f GVHD is relatively minor compared with donor
nti-host major histocompatibility antigen immune
ecognition. In addition, earlier treatment of the re-
ipients with PEG sTNF-RI before irradiation may
e effective in limiting a “cytokine storm” after 920-
Gy TBI.
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